The thin line between hope and hype in biomarker research

JAMA

Volumn 305, Issue 21, 2011, Pages 2229-2230

  Bossuyt, Patrick M M ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER;

CANCER RISK; CARDIOVASCULAR RISK; COLON CANCER; EDITORIAL; GENETIC LINKAGE; HUMAN; HYPERHOMOCYSTEINEMIA; MEDICAL LITERATURE; MEDICAL RESEARCH; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SAMPLE SIZE; TUMOR SUPPRESSOR GENE; EQUIPMENT; META ANALYSIS (TOPIC); METHODOLOGY; NOTE;

BIOLOGICAL MARKERS; EFFECT MODIFIERS (EPIDEMIOLOGY); HUMANS; META-ANALYSIS AS TOPIC; RESEARCH DESIGN; RISK ASSESSMENT; SAMPLE SIZE;

EID: 79957833988     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2011.729     Document Type: Editorial

References (11)

1. Rifai N, Gillette MA, Carr SA. Protein biomarker discovery and validation: the long and uncertain path to clinical utility. Nat Biotechnol. 2006;24(8):971-983. (Pubitemid 44215392)
2. Diamandis EP. Cancer biomarkers: can we turn recent failures into success? J Natl Cancer Inst. 2010;102(19):1462-1467.
3. Ioannidis JPA, Panagiotou OA. Comparison of effect sizes associated with biomarkers reported in highly cited individual articles and in subsequent meta-analyses. JAMA. 2011;305(21):2200-2210.
4. Ford D, Easton DF, Bishop DT, Narod SA, Goldgar DE; Breast Cancer Linkage Consortium. Risks of cancer in BRCA1-mutation carriers. Lancet. 1994;343(8899):692-695.
5. Friedenson B. BRCA1 and BRCA2 pathways and the risk of cancers other than breast or ovarian. MedGenMed. 2005;7(2):60.
6. Niell BL, Rennert G, Bonner JD, Almog R, Tomsho LP, Gruber SB. BRCA1 and BRCA2 founder mutations and the risk of colorectal cancer. J Natl Cancer Inst. 2004;96(1):15-21. (Pubitemid 38180955)
7. Clarke R, Daly L, Robinson K, et al. Hyperhomocysteinemia: an independent risk factor for vascular disease. N Engl J Med. 1991;324(17):1149-1155.
8. Cleophas TJ, Hornstra N, van Hoogstraten B, van der Meulen J. Homocysteine, a risk factor for coronary artery disease or not? a meta-analysis. Am J Cardiol. 2000;86(9):1005-1009.
9. Rutjes AW, Reitsma JB, Vandenbroucke JP, Glas AS, Bossuyt PM. Case-control and two-gate designs in diagnostic accuracy studies. Clin Chem. 2005;51(8):1335-1341. (Pubitemid 41060863)
10. Pepe MS, Feng Z, Janes H, Bossuyt PM, Potter JD. Pivotal evaluation of the accuracy of a biomarker used for classification or prediction: standards for study design. J Natl Cancer Inst. 2008;100(20):1432-1438.
11. Bossuyt PM, Reitsma JB, Bruns DE, et al; Standards for Reporting of Diagnostic Accuracy. Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative. BMJ. 2003;326(7379):41-44.